Clinical Trials Directory

Trials / Completed

CompletedNCT02484820

Prevention of Preterm Birth in Singletons Using Pessary After Resolutive Threatened Preterm Labor

PREMAPESSAIRE: Prevention of Preterm Birth in Singletons Using Pessary After Resolutive Threatened Preterm Labor: a Prospective, Randomized Monocentric Clinical Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
168 (actual)
Sponsor
Centre Hospitalier Universitaire de Saint Etienne · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

In France, threatened preterm labour concerns 6.5% of pregnancies and is associated with a premature birth in 25.4% of cases. After 48 hours effective tocolysis, patients do not receive any further treatment while their risk of premature birth has risen from 6.5% to 25%. A pessary is a silicone ring encircling the cervix. It was initially used as medical treatment of genital prolapse but studies were also conducted for pregnant women in 2 high-risk premature birth situations: cervical incompetence and twin pregnancies. The multicenter PECEP trial conducted by Goya and al. in asymptomatic short cervix patients between 18 and 22 weeks of gestation showed a significant reduction of premature birth before 34 and 37 weeks of gestation. Thereby, the investigator assume that use of pessaries in patients presenting a resolutive threatened preterm labor will also be effective. To evaluate this hypothesis, the investigator designed a randomized prospective single-center open clinical trial comparing pessary associated with standard care (1st group) versus standard care only (2nd group) in patients experiencing an episode of resolutive threatened preterm labor.

Conditions

Interventions

TypeNameDescription
DEVICESilicone pessarySilicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)

Timeline

Start date
2015-12-01
Primary completion
2022-10-08
Completion
2023-01-31
First posted
2015-06-30
Last updated
2023-05-24

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02484820. Inclusion in this directory is not an endorsement.